SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

Astellas Pharma Inc. (4503.T) News

Track canonical SquawkNews coverage tagged to 4503.T, Astellas Pharma Inc.. This hub brings together deduplicated headlines about tokyo, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 1 indexed stories across 1 publication days and is ordered by the same first-publication timeline used by LiveCast.

Symbol 4503.T Asset equity Sector Markets 90 days 1 Last 2,371 Updated Sep 23, 2026, 11:31 PM UTC Open live news feed
H Astellas starts Phase 3 trial of setidegrasib versus docetaxel in KRAS G12D — mutated NSCLC Astellas dosed the first patient in a Phase 3 trial of setidegrasib for previously treated KRAS G12D-mutated advanced NSCLC. Study pits the investigational KRAS G12D protein degrader against docetaxel, targeting patients MACRO | Sep 23, 2026, 11:31 PM UTC